Introduction
============

Plasma cell proliferative disorders are characterized by clonal proliferation of plasma cells, which produce either entire immunoglobulins (Igs) or Ig fragments ([@b1-ol-0-0-3669]). Monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) are the most common plasma cell proliferative disorders ([@b2-ol-0-0-3669]). Approximately 1% of adults \>50 years old have MGUS, with a 14-fold risk of developing MM. In 2012, there were 11,425 new patients with myeloma globally, and it is predicted that MM will be diagnosed in over 2,000 patients in the United States alone in 2015 ([@b3-ol-0-0-3669]). It is currently unknown whether the occurrence of focal segmental glomerulosclerosis (FSGS) in these patients is associated with the primary disease ([@b1-ol-0-0-3669]). Therapy for secondary FSGS should be directed at the underlying disorder, and corticosteroids are the mainstay of treatment for idiopathic FSGS ([@b4-ol-0-0-3669]). Furthermore, following a retrospective review of FSGS and MM English-language studies, nine publications were identified. Of these studies, seven demonstrated an association between FSGS and plasma cell proliferative disorders ([@b2-ol-0-0-3669],[@b5-ol-0-0-3669]--[@b10-ol-0-0-3669]). However, the other two studies indicated little or no correlation between the two conditions ([@b11-ol-0-0-3669],[@b12-ol-0-0-3669]). As FSGS and MM occur infrequently in the same patient and there are few relevant previous studies, the association between them remains unclear. The current study describes a confirmed case of MM in a patient diagnosed with FSGS and renal amyloidosis on two successive renal biopsies. According to the literature, a correlation between the two disorders may be present. Written informed consent was obtained from the patient for the publication of this case report.

Case report
===========

In April 2012, a 45-year-old male patient presented to the Chinese People\'s Liberation Army General Hospital (Beijing, China) with intermittent edema in the lower extremities, fever and fatigue. The patient had previously been diagnosed with nephrotic syndrome (NS) one year earlier at China-Japan Friendship Hospital (Beijing, China). The pathology report on the renal biopsy performed in the previous hospital indicated tip variant FSGS ([Fig. 1](#f1-ol-0-0-3669){ref-type="fig"}). Following treatment with glucocorticoids and tripterygium glycosides for one year ([Table I](#tI-ol-0-0-3669){ref-type="table"}), the patient\'s urine protein levels decreased, but the serum creatinine levels increased. Additionally, the patient\'s blood pressure and hemoglobin levels progressively decreased ([Table II](#tII-ol-0-0-3669){ref-type="table"}). Physical examination revealed the patient had a temperature of 37°C (normal range, 36--37°C) and a body-mass index of 26.1 kg/m^2^ (normal range, 18.5--22.9 kg/m^2^).

Laboratory examinations revealed a calcium level of 2.19 mmol/l (normal range, 2.09--2.54 mmol/l). The serum immunoglobulin G (IgG) level was 2,950.0 mg/dl (normal range, 700--1,600 mg/dl), the κ-light chain level was 16.6 mg/dl (normal range, 170--370 mg/dl) and the λ-light chain level was 810.0 mg/dl (normal range, 90--210 mg/dl). Serum immunofixation electrophoresis revealed IgG λ MGUS. The patient\'s urinary κ-light chain level was 1.36 mg/dl (normal range, 0--0.79 mg/dl) and the λ-light chain level was 135.0 mg/dl (normal range, 0--0.43 mg/dl). Ultrasound of the renal artery indicated an increased resistance index for the initial segment, and lesions in the renal microvasculature. Ultrasound revealed that the left and right kidneys measured 12.9×7.8×6.4 cm and 13.7×7.0×5.7 cm, respectively (normal range, 10.0--12.0×5.0--6.0×3.0--4.0 cm). A bone marrow biopsy revealed that 36% of the plasma cells were abnormal and a diagnosis of IgG λ-type MM was formed.

Renal biopsy. Periodic acid-Schiff (PAS) staining revealed 16 intact glomeruli with normal volumes. Although there was global sclerosis in one glomerulus (6.3%), there was no glomerular adhesion to the Bowman\'s capsule, segmental sclerosis or glomerular crescent. Furthermore, there was diffuse mild-to-moderate mesangial broadening, but no mesangial cell proliferation. The PAS staining was light in the mesangial area and there was a deposit of a homogeneous, protein-like substance, which was also observed in the renal interstitium and on the walls of the renal artery. In addition, a number of capillary loops exhibited restricted openings ([Fig. 2](#f2-ol-0-0-3669){ref-type="fig"}). The renal tubules were diffuse and severely atrophied, and protein casts were visible. A few plasma cells were observed to be diffused through interstitial spaces. Immunohistochemistry demonstrated that the glomerular and tubular epithelial cells were λ chain-positive and κ chain-negative ([Figs. 3](#f3-ol-0-0-3669){ref-type="fig"} and [4](#f4-ol-0-0-3669){ref-type="fig"}). Electron microscopy revealed collagen fiber hyperplasia ([Figs. 5](#f5-ol-0-0-3669){ref-type="fig"} and [6](#f6-ol-0-0-3669){ref-type="fig"}).

Treatment and outcomes. Following discharge, the patient returned to a local hospital to receive chemotherapy for the MM. The patient\'s oncologist commenced treatment for MM with vincristine, doxorubicin and dexamethasone. Following three cycles of drug treatment, the NS was resolved and renal function returned to normal. Upon follow-up examination, the patient\'s IgG level was 1,480 mg/dl, the κ-light chain level was 316 mg/dl and the λ-light chain was 91 mg/dl. No antibiotics were administered and the patient\'s body temperature returned to a normal level. The patient has since been lost to follow-up.

Discussion
==========

FSGS is divided into primary and secondary subtypes, and there are several known causes of the latter. FSGS secondary to the hematological tumors T-cell lymphoma ([@b13-ol-0-0-3669]) or Hodgkin\'s lymphoma ([@b14-ol-0-0-3669]) are the most common and their associations are clear. FSGS secondary to a large granular lymphocytosis ([@b15-ol-0-0-3669]) is less common, but their association has also been documented. Cases of FSGS with MM or MGUS ([@b2-ol-0-0-3669]) are rare and the link between them is unclear and speculative.

The patient described in the current study was pathologically diagnosed with FSGS one year prior to admission. However, the NS did not resolve following first-line treatment and the patient\'s renal function declined. Several phenomena associated with MM were noted, such as anemia that did not parallel the decline in renal function, a reduction in blood pressure that was associated with drug utilization and an increased monoclonal immunoglobulin level in the serum. Therefore, while forming the diagnosis of MM via bone marrow biopsy, a repeat renal biopsy was performed on the patient, which confirmed renal amyloidosis.

Valizadeh *et al* ([@b10-ol-0-0-3669]) reported the case of a patient who had been pathological diagnosed with FSGS and was confirmed with MM upon follow-up. The study speculated that MM may be a rare secondary occurrence to FSGS. Although the present patient was diagnosed with renal amyloidosis after MM, a missed diagnosis of FSGS-like lesions as a result of not performing serial pathological sections cannot be excluded. FSGS is a morphological diagnostic term. Secondary FSGS can be a morphological change in a variety of diseases that develop to a certain stage rather than being caused by a single disease. Secondary FSGS has relatively clear risk factors and FSGS-like changes are usually present during the development of primary glomerular diseases ([@b4-ol-0-0-3669]). Electron microscopy (EM) is currently, the best method for identifying FSGS, and primary FSGS is highly suggested if it indicates the disappearance of \>80% of diffuse foot processes ([@b16-ol-0-0-3669]). However, EM for the present study indicated renal amyloidosis without changes in the foot processes. On this basis, the possibility of MM combined with primary FSGS was excluded.

The patient\'s reduced blood pressure indicated a decline in vascular elasticity and suggested the deposition of amyloid substances on the vascular wall. Ultrasound of the renal artery demonstrated an increased resistance index of the initial segment. This may have been due to amyloid substances on the walls of the renal microvasculature narrowing the luminal spaces or to the deposition of amyloid substances in the mesangial area that may have restricted the openings of the capillary loops. Furthermore, the renal pathology results confirmed a similar inference. We hypothesize that restricted openings of certain capillary loops are compensated for by the capillary loops with unobstructed openings, and increased pressure and perfusion inside the glomeruli are inevitable. This leads to secondary FSGS by compensatory changes, which negatively affect the structure and function of the glomeruli. Thus, from the pathophysiological perspective, the renal pathology of patients may indeed demonstrate FSGS. However, the study by Valizadeh *et al* ([@b10-ol-0-0-3669]) did not repeat the renal biopsy following the patient\'s MM diagnosis and did not perform Congo red staining or light chain immunological testing on the original pathological sections. Therefore, the pathological changes in the kidney could not be confirmed following the MM diagnosis.

Studies on the association between monoclonal gammopathies and FSGS are rare. Only nine publications were identified in a retrospective review of the English-language literature ([Table III](#tIII-ol-0-0-3669){ref-type="table"}). Of these studies, three suggested that there was little or no correlation between FSGS and plasma cell proliferative disorders. In a study by Shah *et al* ([@b12-ol-0-0-3669]), the NS of the patient was not resolved by hormone therapy, however, the patient\'s smoldering MM did improve. Paueksakon *et al* ([@b1-ol-0-0-3669]) identified that 13 out of 87 (14.9%) patients with MGUS and renal damage had FSGS-like lesions, and thus, the FSGS was not considered to be primary. Charney and Wasser ([@b11-ol-0-0-3669]) demonstrated in their study population that obesity and sleep apnea were more relevant to FSGS. These studies did not identify a correlation between these two diseases, as there was no evidence of MM-induced renal damage, such as amyloidosis, cast nephropathy or plasma cell infiltration. However, a secondary FSGS diagnosis does not require renal damage from the primary disease. In addition, the treatment of MM in the study by Charney and Wasser ([@b11-ol-0-0-3669]) was not continuous, remission rates were poor and renal failure also progressed to end-stage renal disease. All of these factors support the notion that the two diseases are associated. While the patients in a study by Shah *et al* ([@b12-ol-0-0-3669]) exhibited a reduction in serum monoclonal protein and light chain protein levels following the use of hormones for 3 months, the proteinuria did not resolve. It is possible that the improvement in secondary FSGS required a longer time than that required to control the primary disease. Treatment was subsequently commenced with cyclophosphamide, which increased the remission rate for MM compared to cyclosporine, and improved the FSGS. The improved therapeutic effect of cyclophosphamide on FSGS during MM supports the association between FSGS and MM. The correlation between FSGS and MM becomes clearer when patients use pamidronate. Treatment of osteolytic complications in MM patients using pamidronate can result in the collapsing variant of FSGS ([@b17-ol-0-0-3669]). The simultaneous occurrence of FSGS and MM is not a coincidence; Dingli *et al* ([@b2-ol-0-0-3669]) reported the cases of 13 patients who were diagnosed with syndromes secondary to plasma cell proliferative disorders (four cases of MM and nine cases of MGUS). For all 13 cases, renal damage improved following treatment of the primary diseases and recurred with the relapse of the primary diseases. Therefore, a common pathogenic link between MGUS and MM is plausible.

Vascular endothelial growth factor (VEGF) and heparanase can change the glomerular permeability and affect the glomerular basement membrane function to cause proteinuria in FSGS ([@b18-ol-0-0-3669]). VEGF and heparanase are overexpressed in MM patients, and VEGF can induce the growth of bone marrow blood vessels ([@b19-ol-0-0-3669],[@b20-ol-0-0-3669]) Heparanase plays important roles in tumor growth, angiogenesis and metabolism. Furthermore, these two proteins are involved in the occurrence and development of MGUS and MM ([@b19-ol-0-0-3669],[@b20-ol-0-0-3669]). Dingli *et al* ([@b2-ol-0-0-3669]) used a causal inference epidemiological method to note the close association between MGUS, MM and FSGS.

The present study indicates that FSGS patients \>40 years old should undergo serum and urinary immune electrophoresis, Congo red staining, and κ- and λ-light chain level analysis routinely to detect plasma cell proliferative disorders and improve the prognosis of potentially associated FSGS. Additionally, repeated renal pathological examinations may be required for a small fraction of patients.
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![Masson trichome staining of kidney tissue (original magnification, ×400).](ol-10-05-2821-g00){#f1-ol-0-0-3669}

![Deposition of a lightly stained, homogeneous, protein-like substance observed in arterial walls and glomerular mesangial areas (periodic acid-Schiff staining; original magnification, ×200).](ol-10-05-2821-g01){#f2-ol-0-0-3669}

![Glomerular and tubular epithelial cells positive for λ-light chains, identified by immunohistochemistry (original magnification, ×400).](ol-10-05-2821-g02){#f3-ol-0-0-3669}

![Glomerular and tubular epithelial cells negative for κ-light chains, identified by immunohistochemistry (original magnification, ×400).](ol-10-05-2821-g03){#f4-ol-0-0-3669}

![Electron micrograph demonstrating no cellular broadening or randomly distributed fibers in the glomerular basement membrane and mesangial areas.](ol-10-05-2821-g04){#f5-ol-0-0-3669}

![Electron micrograph demonstrating collagen fiber hyperplasia and randomly distributed fibrous tissues in the renal interstitium.](ol-10-05-2821-g05){#f6-ol-0-0-3669}

###### 

Continuous treatments in the previous hospital.

                       Treatment at indicated times                                          
  -------------------- ------------------------------ ------------ ------------ ------------ ------------
  Methylprednisolone   40 mg i.v. 3D                                                         
  Prednisone           60 mg q.d.                     30 mg q.d.   10 mg q.d.   25 mg q.d.   10 mg q.d.
  TGT                                                 20 mg tid    40 mg tid    20 mg tid    20 mg tid
  Leflunomide                                                                                10 mg q.d.

TGT, tripterygium glycosides tablets; i.v., intravenous injection; 3D, daily for 3 days; q.d., every day; tid, three times per day.

###### 

Blood pressure and laboratory test results from the previous hospital treatment.

                          Values at indicated times                                   
  ----------------------- --------------------------- ------- ------- ------- ------- -------
  SBP, mmHg               130                         111     127     107       87      85
  DBP, mmHg                 80                          78      72      67      59      55
  MBP, mmHg               123                         115     114     103       88      83
  24-h urine protein, g   21.03                       5.15    6.66    9.57    9.45    7.53
  WBC, 1×10^9^ cells/l    8.65                        13.5    15.9    14.3      12    8.97
  HGB, g/l                111                         147     138     127       82      72
  ALB, g/l                16.4                        23.1    22.8    20.4    23.3    15.4
  Scr, µmol/l               70                        64.52   68.07   69.84   91.05   100
  BUN, mmol/l             5.65                        6.65    6.76    5.72    5.83    5.26
  UA, µmol/l              366                         395     464     514     544     419
  GFR, ml/min/1.73m^2^    80.70                       94.96   89.38   86.17   68.75   55.84

SBP, systolic blood pressure; DBP, diastolic blood pressure; MBP, mean arterial pressure; WBC, white blood cell count; HGB, hemoglobin; ALB, albumin; Scr, serum creatine; BUN, blood urea nitrogen; UA, uric acid; GFR, glomerular filtration rate.

###### 

Major characteristics of the nine publications studying MG combined with FSGS.

                                                                       Age, years                                                                                                                                                                                                                                                                                                                                                                                                                       
  ----------------------------------------- -------------------------- ------------------------------------ ---- -------------------------- ----------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------- --- -------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------
  Dingli *et al* ([@b2-ol-0-0-3669])        Male (n=11) Female (n=2)   64                                   65   MGUS (n=9) Myeloma (n=4)   NS (n=3) Nephrotic proteinuria \>3 g/24 h (n=6)                                                             No collapsing variant FSGS                                                         Y   Melphalan and prednisone (n=2) Intermittent dexamethasone then high-dose melphalan and autologous stem cell transplantation (n=2)                        Proteinuria decreased in 4 patients and stabilized in 3 of the 4; relapse of myeloma was associated with increasing proteinuria in 1 patient
  Shah *et al* ([@b5-ol-0-0-3669])          Female                     51                                   51   IgAκ MM                    Scr 3.5 mg/dl, Ccr 46 ml/min and NS (Alb, 23 g/l; urine protein, 32.6 g/24 h)                               Collapsing variant FSGS                                                            Y   i\) Symptomatic treatment ii) Four cycles of VAD chemotherapy iii) High-dose melphalan therapy with stem cell rescue six months after VAD chemotherapy   14 months after initial presentation, patient was in remission of NS; renal function had improved (Scr 1.4 mg/dl)
  Charney and Wasser ([@b11-ol-0-0-3669])   Male                       36                                   31   IgGκ MM                    Scr 1.7 mg/dl, urine protein 9.5 g/24 h                                                                     1\. FSGS with hyalinosis, likely secondary, 2. Monoclonal plasma cell infiltrate   N   Three cycles of VAD                                                                                                                                      Renal function continually deteriorated to the point that vascular access was instituted for hemodialysis therapy
  Jain *et al* ([@b6-ol-0-0-3669])          Male                       70                                   72   MGUS                       Scr increased from 1.1 mg/dl to 5 mg/dl within four months and nephrotic range proteinuria (PCR 4.8 g/mg)   Collapsing variant FSGS                                                            Y   Unknown                                                                                                                                                  Scr 6.4 mg/dl on discharge
  Ashrafi *et al* ([@b7-ol-0-0-3669])       Male                       58 (9 months after FSGS diagnosis)   58   κ MM                       1\. Scr 1.1 mg/dl, urine protein 2.2 g/24 h 2. ARF diagnosed 9 months after FSGS                            Tip variant FSGS                                                                   Y   Thalidomide, dexamethasone, pamidronate and autologous bone marrow transplantation                                                                       After one week of treatment, the patient\'s Scr had decreased
  Torun *et al* ([@b8-ol-0-0-3669])         Male                       44                                   46   κ light MGUS               Scr 1.7 mg/dl, Ccr 49 ml/min and NS (urine protein 21.3 g/24 h)                                             FSGS                                                                               Y   Immunosuppressive treatment and autologous bone marrow transplantation                                                                                   Scr 1.4 mg/dl and remission of NS
  Matsuyama *et al* ([@b9-ol-0-0-3669])     Female                     40                                   40   IgG κ MGUS                 CRF and NS                                                                                                  FSGS with widespread deposition of large crystalline inclusions in podocytes       Y   Unknown                                                                                                                                                  Unknown
  Shah *et al* ([@b12-ol-0-0-3669])         Male                       62                                   62   SMM                        Scr 0.8 mg/dl and urine protein 4.3 g/24 h                                                                  Collapsing variant FSGS                                                            N   Glucocorticoids and cyclophosphamide                                                                                                                     Urine protein 3.8 g/24 h
  Valizadeh *et al* ([@b10-ol-0-0-3669])    Male                       63 (7 months after FSGS diagnosis)   63   MM                         Proteinuria, hematuria and renal failure                                                                    FSGS                                                                               Y   Unknown                                                                                                                                                  Unknown

FSGS, focal segmental glomerulosclerosis; MGUS, monoclonal gammopathy of undetermined significance; NS, nephrotic syndrome; MM, multiple myeloma; Scr, serum creatinine; Ccr, creatinine clearance; Alb, serum albumin; VAD, vincristine, Adriamycin and dexamethasone; PCR, protein creatinine ratio; UN, unknown; ARF, acute renal failure; CRF, chronic renal failure; SMM, smoldering MM; Y, yes; N, no.
